Role of motility in chronic diarrhoea

Neurogastroenterology and Motility

Volumn 18, Issue 12, 2006, Pages 1045-1055

  Spiller, R ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Diarrhoea; Intestine; Motility; Propulsion; Secretion; Serotonin

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; BILE ACID; BUDESONIDE; CARBOHYDRATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILANSETRON; CODEINE; COLESTYRAMINE; DESIPRAMINE; LOPERAMIDE; OCTREOTIDE; ONDANSETRON; OPIATE DERIVATIVE; PREDNISOLONE; PROBIOTIC AGENT; SEROTONIN; SEROTONIN 3 ANTAGONIST;

BACTERIAL OVERGROWTH; BLURRED VISION; CARBOHYDRATE INTOLERANCE; COLON ABSORPTION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FECES ANALYSIS; FOOD INTAKE; HUMAN; INTESTINE MOTILITY; INTESTINE MUCOSA; IRRITABLE COLON; MAST CELL; MICTURITION DISORDER; NONHUMAN; OBESITY; PERISTALSIS; POSTGASTRECTOMY SYNDROME; PRIORITY JOURNAL; REVIEW; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; SMALL INTESTINE ABSORPTION; STOMACH EMPTYING; WATER CONTENT; XEROSTOMIA;

ANIMALS; CHRONIC DISEASE; DIARRHEA; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINES;

EID: 33750974809     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2006.00836.x     Document Type: Review

References (68)

1. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33: 818-24.
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
3. Racke K, Reimann A, Schworer H, Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. Behav Brain Res 1996; 73: 83-7.
4. Kellum JM, Albuquerque FC, Stoner MC, Harris RP. Stroking human jejunal mucosa induces 5-HT release and Cl- secretion via afferent neurons and 5-HT4 receptors. Am J Physiol 1999; 277: G515-20.
5. Grider JR, Kuemmerle JF, Jin JG. 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1p receptors on sensory CGRP neurons. Am J Physiol 1996; 270: G778-82.
6. Foxx-Orenstein AE, Kuemmerle JF, Grider JR. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 1996; 111: 1281-90.
7. Oosterbosch L, von der OM, Valdovinos MA, Kost LJ, Phillips SF, Camilleri M. Effects of serotonin on rat ileocolonic transit and fluid transfer in vivo: possible mechanisms of action. Gut 1993; 34: 794-8.
8. Lordal M, Wallen H, Hjemdahl P, Beck O, Hellstrom PM. Concentration-dependent stimulation of intestinal phase III of migrating motor complex by circulating serotonin in humans. Clin Sci (Colch) 1998; 94: 663-70.
9. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 159-66.
10. Coleman NS, Marciani L, Blackshaw E et al. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther 2003; 18: 1039-48.
11. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
12. De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 603-12.
13. Debongnie JC, Phillips SF. Capacity of the human colon to absorb fluid. Gastroenterology 1978; 74: 698-703.
14. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest 1971; 50: 1569-77.
15. Spiller RC, Brown ML, Phillips SF. Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acid. Gastroenterology 1986; 91: 100-7.
16. Rao SSC, Edwards CA, Austen CJ, Bruce C, Read NW. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988; 94: 928-32.
17. Cook IJ, Furukawa Y, Panagopoulos V, Collins PJ, Dent J. Relationships between spatial patterns of colonic pressure and individual movements of content. Am J Physiol Gastrointest Liver Physiol 2000; 278: G329-41.
18. Bazzocchi G, Ellis J, Villanueva-Meyer J, Reddy SN, Mena I, Snape WJ Jr. Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations. Gastroenterology 1991; 101: 1298-306.
19. Steadman C, Kerlin P. Response of the human intestine to high volume infusion. Gut 1994; 35: 641-5.
20. Kamath PS, Phillips SF, Zinsmeister AR. Short-chain fatty acids stimulate ileal motility in humans. Gastroenterology 1988; 95: 1496-502.
21. Husebye E, Skar V, Hoverstad T, Iversen T, Melby K. Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology 1995; 109: 1078-89.
22. Riordan SM, McIver CJ, Walker BM, Duncombe VM, Bolin TD, Thomas MC. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996; 91: 1795-803.
23. Williams AJK, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption - a review of clinical presentation, diagnosis, and response to treatment. Gut 1991; 32: 1004-6.
24. Niaz SK, Sandrasegaran K, Renny FH, Jones BJ. Postinfective diarrhoea and bile acid malabsorption. J R Coll Physicians Lond 1997; 31: 53-6.
25. Sinha L, Liston R, Testa HJ, Moriarty KJ. Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 1998; 12: 839-44.
26. Christopher NL, Bayless TM. Role of the small bowel and colon in lactose-induced diarrhea. Gastroenterology 1971; 60: 845-52.
27. Swallow DM. Genetics of lactase persistence and lactose intolerance. Annu Rev Genet 2003; 37: 197-219.
28. Sethi AK, Sarna SK. Colonic motor activity in acute colitis in conscious dogs. Gastroenterology 1991; 100: 954-63.
29. Reddy SN, Bazzocchi G, Chan S et al. Colonic motility and transit in health and ulcerative colitis. Gastroenterology 1991; 101: 1289-97.
30. Kellow JE, Gill RC, Wingate DL. Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome. Gastroenterology 1990; 98: 1208-18.
31. Schmidt T, Hackelsberger N, Widmer R, Meisel C, Pfeiffer A, Kaess H. Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 581-9.
32. Small PK, Loudon MA, Hau CM, Noor N, Campbell FC. Large-scale ambulatory study of postprandial jejunal motility in irritable bowel syndrome. Scand J Gastroenterol 1997; 32: 39-47.
33. Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998; 10: 415-21.
34. Clemens CH, Samsom M, Roelofs JM, Berge Henegouwen GP, Smout AJ. Association between pain episodes and high amplitude propagated pressure waves in patients with irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1838-43.
35. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001; 96: 1499-506.
36. Clemens CH, Samsom M, Berge Henegouwen GP, Smout AJ. Abnormalities of left colonic motility in ambulant nonconstipated patients with irritable bowel syndrome. Dig Dis Sci 2003; 48: 74-82.
37. Fukudo S, Kanazawa M, Kano M et al. Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol 2002; 37(Suppl. 14): 145-50.
38. Bassotti G, Chistolini F, Marinozzi G, Morelli A. Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome. Digestion 2003; 68: 178-83.
39. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825-30.
40. Narducci F, Snape WJJ, Battle WM, London RL, Cohen S. Increased colonic motility during exposure to a stressful situation. Dig Dis Sci 1985; 30: 40-4.
41. Tache Y, Martinez V, Million M, Rivier J. Corticotropin-releasing factor and the brain-gut motor response to stress. Can J Gastroenterol 1999; 13(Suppl. A): 18A-25A.
42. Tillisch K, Mayer EA, Labus JS, Stains J, Chang L, Naliboff BD. Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 2005; 54: 1396-401.
43. Elsenbruch S, Orr WC. Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses. Am J Gastroenterol 2001; 96: 460-6.
44. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998; 42: 845-9.
45. Sagami Y, Shimada Y, Tayama J et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004; 53: 958-64.
46. Ambrosetti P, Robert JH, Witzig JA et al. Acute left colonic diverticulitis: a prospective analysis of 226 consecutive cases. Surgery 1994; 115: 546-50.
47. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
48. Dunlop SP, Coleman NS, Blackshaw E et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-57.
49. Clemens CH, Samsom M, Berge Henegouwen GP, Fabri M, Smout AJ. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2002; 16: 993-1002.
50. Coleman N, Foley S, Dunlop SP et al. Abnormalities of serotonin metabolism and its relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006; 4: 874-881.
51. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
52. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-101.
53. Million M, Wang L, Wang Y et al. CRF2 receptor activation prevents colorectal distension-induced visceral pain and spinal ERK1/2 phosphorylation in rats. Gut 2005; 55: 172-181.
54. Santos J, Saperas E, Nogueiras C et al. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology 1998; 114: 640-8.
55. Guilarte M, Santos J, De Torres I et al. Extensive gut mucosal involvement in diarrhea-prone patients disclosed by jejunal mast cell infiltration. Gastroenterology 2006; 125: A61.
56. Vergnolle N. Clinical relevance of proteinase activated receptors (pars) in the gut. Gut 2005; 54: 867-74.
57. Naslund E, King N, Mansten S et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004; 91: 439-46.
58. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166-70.
59. Naslund E, Barkeling B, King N et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304-11.
60. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-8.
61. Penning C, Vecht J, Masclee AA. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome. Aliment Pharmacol Ther 2005; 22: 963-9.
62. Attar A, Flourie B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117: 794-7.
63. Lisker R, Solomons NW, Briceno RP, Mata MR. Lactase and placebo in the management of the irritable bowel syndrome: a double-blind, cross-over study. Am J Gastroenterol 1989; 84: 756-62.
64. Woods SC, Benoit SC, Clegg DJ, Seeley RJ. Regulation of energy homeostasis by peripheral signals. Best Pract Res Clin Endocrinol Metab 2004; 18: 497-515.
65. Tack J, Vos R, Gevers A-M, Janssens J. Alosetron: more than just a constipating drug? A comparison of the effects of alosetron and of loperamide on colonic sensorimotor function in man. A-752. Gastroenterology 2001; 120(Suppl. 1): A-752.
66. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86.
67. Clouse RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut 2005; 54: 1332-41.
68. Drossman DA, Toner BB, Whitehead WE et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31.